Last reviewed · How we verify
Group O (Oxycodone)
Oxycodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and pain relief.
Oxycodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and pain relief. Used for Moderate to severe acute pain, Moderate to severe chronic pain.
At a glance
| Generic name | Group O (Oxycodone) |
|---|---|
| Sponsor | Medical University of Silesia |
| Drug class | Opioid analgesic |
| Target | Mu-opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Oxycodone acts as a mu-opioid receptor agonist, binding to these receptors throughout the brain and spinal cord to modulate pain perception and transmission. By activating mu-opioid receptors, it increases pain threshold and reduces the emotional response to pain. It is commonly used for moderate to severe acute and chronic pain management.
Approved indications
- Moderate to severe acute pain
- Moderate to severe chronic pain
Common side effects
- Constipation
- Nausea
- Drowsiness
- Dizziness
- Vomiting
- Respiratory depression
- Dependence and addiction potential
Key clinical trials
- Comparison of the Efficacy and Safety of Intravenous Buprenorphine Administered Via PCA System Versus Oxycodone in the Management of Postoperative Pain After Video-Assisted Thoracoscopic Surgery (PHASE4)
- Clinical Study of Equivalent Doses of Oxycodone or Tegileridine on Patients Undergoing Gynecological Laparoscopic Hysterectomy (PHASE4)
- Comparative Effectiveness Study for Surgery vs. Non-Surgery in Patients With Low Back Pain (NA)
- Comparison of the Effects of Fentanyl, Oxycodone, Butorphanol on Gastrointestinal Function (NA)
- Oxycodone Extended-release in the Treatment of Perioperative Pain in Patients Undergoing Orthopaedic Surgery (PHASE4)
- Morphine vs. Oxycodone for Postoperative Pain Management (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Group O (Oxycodone) CI brief — competitive landscape report
- Group O (Oxycodone) updates RSS · CI watch RSS
- Medical University of Silesia portfolio CI